One of the key differences between medical cannabis and other more traditional treatments is the highly personalised nature of how each patient is affected.
Multi-state operators, or MSO’s, have long represented the biggest and most influential cannabis players in North America. Yet, as that market matures and expansion opportunities dwindle a new trend is emerging – the rise of ‘multi-country operators’ (MCOs).
SOMAÍ Pharmaceuticals, a leading EU-GMP vertically integrated Multi-Country Operator (MCO) specializing in cannabinoid-based medicines, is proud to announce its entry into
SOMAÍ Pharmaceuticals (“SOMAÍ”), a fully vertically integrated Multi-Country Operator (MCO) in the global medical cannabis markets, is proud to announce
UK medical cannabis patients are facing multiple challenges that are preventing the adoption of the legal market. From stigmatisation and
Written by Michael Sassano, CEO, Somai Pharmaceuticals Recently, I have become more optimistic about the global landscape of medical cannabis and the
Written by Michael Sassano, CEO, Somai Pharmaceuticals On January 12, the United States Department of Health and Human Services (HHS)
Last month, Portugal’s government announced plans to establish a working group to explore the regulation of adult-use cannabis, with a
Last week, Germany took the first step towards wholesale cannabis legalisation after the federal cabinet waved through the long-awaited draft
Albania has become the latest European country to officially legalise the ‘cultivation and processing of the cannabis plant and the
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
